View Item 

Show simple item record

Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer

dc.contributor.authorHoppe, Bradford S.en_US
dc.contributor.authorMichalski, Jeff M.en_US
dc.contributor.authorMendenhall, Nancy P.en_US
dc.contributor.authorMorris, Christopher G.en_US
dc.contributor.authorHenderson, Randal H.en_US
dc.contributor.authorNichols, Romaine C.en_US
dc.contributor.authorMendenhall, William M.en_US
dc.contributor.authorWilliams, Christopher R.en_US
dc.contributor.authorRegan, Meredith M.en_US
dc.contributor.authorChipman, Jonathan J.en_US
dc.contributor.authorCrociani, Catrina M.en_US
dc.contributor.authorSandler, Howard M.en_US
dc.contributor.authorSanda, Martin G.en_US
dc.contributor.authorHamstra, Daniel A.en_US
dc.date.accessioned2014-05-21T18:02:50Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-05-21T18:02:50Z
dc.date.issued2014-04-01en_US
dc.identifier.citationHoppe, Bradford S.; Michalski, Jeff M.; Mendenhall, Nancy P.; Morris, Christopher G.; Henderson, Randal H.; Nichols, Romaine C.; Mendenhall, William M.; Williams, Christopher R.; Regan, Meredith M.; Chipman, Jonathan J.; Crociani, Catrina M.; Sandler, Howard M.; Sanda, Martin G.; Hamstra, Daniel A. (2014). "Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer." Cancer 120(7): 1076-1082.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106701
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherProstate Canceren_US
dc.subject.otherProton Therapyen_US
dc.subject.otherIntensity‐Modulated Radiotherapyen_US
dc.subject.otherOutcomesen_US
dc.subject.otherGenitourinaryen_US
dc.titleComparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106701/1/cncr28536.pdf
dc.identifier.doi10.1002/cncr.28536en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceClark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001; 39: 1118 ‐ 1130.en_US
dc.identifier.citedreferenceZelefsky MJ, Fuks Z, Hunt M, et al. High‐dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53: 1111 ‐ 1116.en_US
dc.identifier.citedreferenceZietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional‐dose with high‐dose conformal radiation therapy in early stage adenocarcinoma of the prostate: long‐term results from Proton Radiation Oncology Group/American College of Radiology 95‐09. J Clin Oncol. 2010; 28: 1106 ‐ 1111.en_US
dc.identifier.citedreferenceNguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517 ‐ 1524.en_US
dc.identifier.citedreferenceBekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity‐modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer [serial online]. Int J Radiat Oncol Biol Phys. 2011; 81: e325 ‐ e334.en_US
dc.identifier.citedreferenceSheets NC, Goldin GH, Meyer AM, et al. Intensity‐modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307: 1611 ‐ 1620.en_US
dc.identifier.citedreferenceKim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol. 2011; 60: 908 ‐ 916.en_US
dc.identifier.citedreferenceYu JB, Soulos PR, Herrin J, et al. Proton versus intensity‐modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105: 25 ‐ 32.en_US
dc.identifier.citedreferenceDeville C, Ben‐Josef E, Vapiwala N. Radiation therapy modalities for prostate cancer [letter]. JAMA 308: 451, 2012; author reply 451‐452.en_US
dc.identifier.citedreferenceMendenhall NP, Schild S, Slater J. Radiation therapy modalities for prostate cancer [letter]. JAMA. 2012; 308: 450 ‐ 451; author reply 451‐452.en_US
dc.identifier.citedreferenceSzymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health‐related quality of life among prostate cancer survivors. Urology. 2010; 76: 1245 ‐ 1250.en_US
dc.identifier.citedreferenceMendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from 3 prospective trials of image‐guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 213 ‐ 221.en_US
dc.identifier.citedreferenceSandler HM, Liu PY, Dunn RL, et al. Reduction in patient‐reported acute morbidity in prostate cancer patients treated with 81‐Gy intensity‐modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010; 75: 1004 ‐ 1008.en_US
dc.identifier.citedreferenceWei JT, Dunn RL, Litwin MS, et al. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health‐related quality of life in men with prostate cancer. Urology. 2000; 56: 899 ‐ 905.en_US
dc.identifier.citedreferenceMiller DC, Sanda MG, Dunn RL, et al. Long‐term outcomes among localized prostate cancer survivors: health‐related quality‐of‐life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005; 23: 2772 ‐ 2780.en_US
dc.identifier.citedreferenceNorman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582 ‐ 592.en_US
dc.identifier.citedreferenceSanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med. 2008; 358: 1250 ‐ 1261.en_US
dc.identifier.citedreferenceHoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012; 118: 4619 ‐ 4626.en_US
dc.identifier.citedreferenceFiorino C, Fellin G, Rancati T, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D‐CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008; 70: 1130 ‐ 1137.en_US
dc.identifier.citedreferenceGray PJ, Paly JJ, Yeap BY, et al. Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013; 119: 1729 ‐ 1735.en_US
dc.identifier.citedreferenceVargas C, Fryer A, Mahajan C, et al. Dose‐volume comparison of proton therapy and intensity‐modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 744 ‐ 751.en_US
dc.identifier.citedreferenceTrofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007; 69: 444 ‐ 453.en_US
dc.identifier.citedreferenceTucker SL, Dong L, Michalski JM, et al. Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94‐06. Int J Radiat Oncol Biol Phys. 2012; 84: 390 ‐ 395.en_US
dc.identifier.citedreferencePeeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 64: 1151 ‐ 1161.en_US
dc.identifier.citedreferenceal‐Abany M, Helgason AR, Cronqvist AK, et al. Toward a definition of a threshold for harmless doses to the anal‐sphincter region and the rectum. Int J Radiat Oncol Biol Phys. 2005; 61: 1035 ‐ 1044.en_US
dc.identifier.citedreferenceResnick MJ, Koyama T, Fan KH, et al. Long‐term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368: 436 ‐ 445.en_US
dc.identifier.citedreferenceHamstra DA, Stenmark MJ, Ritter T, et al. Age and comorbid illness are associated with late rectal toxicity following dose‐escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 85: 1246 ‐ 1253.en_US
dc.identifier.citedreferenceKrol R, Smeenk RJ, van Lin EN, et al. Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy. Int J Colorectal Dis. 2013; 28: 519 ‐ 526.en_US
dc.identifier.citedreferenceYeoh EK, Holloway RH, Fraser RJ, et al. Pathophysiology and natural history of anorectal sequelae following radiation therapy for carcinoma of the prostate [serial online]. Int J Radiat Oncol Biol Phys. 2012; 84: e593 ‐ e599.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28536.pdf
Size:
194.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.